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1726-4Serum oxidative stress and chronic obstructive pulmonary diseaseThe classical definition of chronic obstructive pulmonary
disease (COPD) is a chronic and progressive airflow limi-
tation, secondary to sustained inflammation of the lungs due to
inhalation of noxious particles. It is well-established that
COPD is not only associated with pulmonary inflammation,
but also with systemic inflammation. Oxidative stress has been
determined to play a central role in the pathogenesis of COPD,
and smoking is the primary environmental factor that can
increase the likelihood that COPD may develop. However,
only one third of smokers will develop COPD,1 suggesting
that the pathogenesis of COPD depends on the interaction
between oxidants and antioxidants. Can et al2 conducted a
case-control study intended to analyze the role of oxidative
stress and serum lipid level in patients with stable COPD to
elucidate an important clinical question about the systemic
oxidative stress and the progress of COPD. For decades, an
imbalance between oxidants and antioxidants has been iden-
tified in smokers and COPD.3 However, many studies focused
on the oxidant/antioxidant imbalance of the pathogenesis of
COPD, whereas less attention has been paid to the role of the
serum lipid and ischemia modified albumin (IMA) levels
associated with this condition. A previous epidemiological
study4 supported the relationship between COPD and athero-
sclerotic cardiovascular disease. Furthermore, the present
study has demonstrated the importance of serum IMA and
oxidized-low density lipoprotein (ox-LDL) in stable COPD
patients. Can et al2 discovered that serum IMA, ox-LDL and
total oxidant status (TOS) were significantly increased and
high density lipoprotein cholesterol (HDL-C) levels were
significantly reduced in patients with COPD compared with
healthy control subjects. Moreover, there was no statistical
difference between COPD and healthy control subjects for the
levels of serum total antioxidant status (TAS), triglycerides,
total cholesterol, and LDL-C.
A growing body of evidence indicates that the oxidant/
antioxidant imbalance plays a key role in enhancing chronic
inflammation and development of COPD.5,6 However, COPD
patients do not manifest an atherogenetic lipid pattern and
their increased risk of artherosclerosis could be attributable to
different factors.7,8 The role of serum lipid profiles in COPD
still remains controversial. The present study shows sig-
nificantly higher serum IMA, TOS, ox-LDL, and lower HDL-
C levels in stable COPD patients compared with controls; but
this is not the case for serum triglycerides, total cholesterol,x.doi.org/10.1016/j.jcma.2015.08.002
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assand LDL-C levels. Therefore, we may hypothesize that the
chronic pulmonary inflammatory component of COPD may
play a central position in initiating systemic endothelial dys-
function through changes in serum oxidative stress rather than
a modification of the serum lipid pattern. The significant
correlation between the increased serum concentrations of
oxidative parameters (IMA, ox-LDL, and TOS) and COPD
severity according to the Global initiative for chronic
Obstructive Lung Disease (GOLD) stages observed in this
study, also supports the hypothesis that the regulation of oxi-
dant/antioxidant balance could be affected in the disease
progression of COPD patients.
Oxidative stress plays an important part in the pathogenesis
of COPD. It is noteworthy that the present study showed
elevated TOS and normal TAS levels in COPD patients. TAS
was measured to evaluate the efficiency of all antioxidants.
The major antioxidants in the lung include mucin, glutathione,
uric acid, proteins (especially albumin), and ascorbic acid.
Oxidants are produced in the lungs by inflammatory cells,
especially neutrophils and macrophages. There is strong evi-
dence that supports the idea of an increased burden of oxidants
in the lungs of patients with stable COPD.3 However, the
overwhelming oxidative stress in COPD is caused by an
increased burden of oxidants and an unequal level of anti-
oxidants. In COPD patients, antioxidants are not enough to
neutralize the excessive load of oxidants, since a normal TAS
level is observed in this study. A previous study9 also indicated
that protective antioxidants are significantly depleted in
alveolar macrophages of COPD patients.
IMA is a sensitive marker in acute ischemic conditions,
especially in myocardial ischemia, skeletal ischemia, and
stroke. It is now well-recognized that cardiovascular death
contributes significantly to the mortality of COPD. This is the
first study to evaluate the relationship between serum IMA and
COPD patients. In the present study, IMA levels are increased
positively in patients with GOLD stages II, III, and IV, com-
pared with controls. Can et al2 concluded that IMA is a useful
marker for the evaluation of chronic inflammation and oxi-
dative stress in COPD. The mechanism of increased serum
IMA levels in COPD is not fully understood. Despite being a
limited study, this research by Can et al2 is an indication that
serum IMA levels might be applied to evaluate the risk of
COPD. More research is needed regarding the effect of
hypoxia on serum IMA levels. The major limitation of theociation. All rights reserved.
688 Editorial / Journal of the Chinese Medical Association 78 (2015) 687e688present study was the small sample size, wherein only 51
patients with stable COPD were enrolled, so the results of this
study need to be treated circumspectly. Future research is
obviously required, but this is an exciting first step.
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